Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   41189   clinical trials with a EudraCT protocol, of which   6743   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2015-005814-31
    Sponsor's Protocol Code Number:ND0612H-012
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2017-04-21
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2015-005814-31
    A.3Full title of the trial
    A multicenter, international, open-label, safety study of ND0612, a solution of levodopa/carbidopa delivered via a pump system as a continuous subcutaneous infusion in subjects with advanced Parkinson's Disease (BeyoND)
    Un estudio multicéntrico, internacional y abierto de la seguridad de ND0612, una solución de levodopa/carbidopa administrada mediante un sistema de bomba como perfusión subcutánea continua en sujetos con enfermedad de Parkinson avanzada (BeyoND)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    -
    A.3.2Name or abbreviated title of the trial where available
    BeyoND
    BeyoND
    A.4.1Sponsor's protocol code numberND0612H-012
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorNeuroDerm Ltd.
    B.1.3.4CountryIsrael
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportNeuroDerm Ltd.
    B.4.2CountryIsrael
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationNeuroDerm Ltd.
    B.5.2Functional name of contact pointYaell Ullmann
    B.5.3 Address:
    B.5.3.1Street AddressRuhrberg Science building - Bell entrance - 5th floor - 3 Pekeris St.
    B.5.3.2Town/ cityRehovot
    B.5.3.3Post code7670212
    B.5.3.4CountryIsrael
    B.5.4Telephone number+972-8-9462729
    B.5.5Fax number+972-8-9461729
    B.5.6E-mailullmann.y@neuroderm.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namelevodopa/carbidopa solution
    D.3.2Product code ND0612
    D.3.4Pharmaceutical form Solution for injection/infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNLevodopa
    D.3.9.1CAS number 59-92-7
    D.3.9.2Current sponsor code-
    D.3.9.3Other descriptive nameLEVODOPA
    D.3.9.4EV Substance CodeSUB08468MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number60
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNcarbidopa
    D.3.9.1CAS number 38821-49-7
    D.3.9.2Current sponsor code-
    D.3.9.3Other descriptive nameCARBIDOPA
    D.3.9.4EV Substance CodeSUB06126MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number7.5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Yes
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Subjects with advanced Parkinson's disease
    Sujetos con enfermedad de Parkinson avanzada
    E.1.1.1Medical condition in easily understood language
    Parkinson's disease
    Enfermedad de Parkinson
    E.1.1.2Therapeutic area Diseases [C] - Nervous System Diseases [C10]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 19.1
    E.1.2Level PT
    E.1.2Classification code 10061536
    E.1.2Term Parkinson's disease
    E.1.2System Organ Class 10029205 - Nervous system disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of the study is to assess the long term safety (systemic and local) and tolerability of continuous SC infusion of ND0612. Assessment will be based on adverse events (AEs), with a focus on infusion site skin reactions and infusion site inspections for erythema, edema, pain, hematoma and nodules (local safety). Tolerability will be assessed based on the percentage of subjects that complete the 12 month treatment period of the study.
    El objetivo principal es evaluar la seguridad a largo plazo (sistémica y local) y la tolerabilidad de la perfusión SC continua de ND0612. La evaluación se basará en los acontecimientos adversos (AA). Asimismo, se prestará especial atención a las reacciones cutáneas en el lugar de perfusión y se hará hincapié en inspecciones del lugar de perfusión para identificar eritemas, edema, dolor, hematomas y nódulos (seguridad local). Se evaluará la tolerabilidad como el porcentaje de sujetos que finalicen el período de tratamiento de 12 meses del estudio.
    E.2.2Secondary objectives of the trial
    Further Safety Objectives: (assessed based on 12 month data):
    • To further assess the safety and tolerability of ND0612 including suicidality (Columbia - Suicide Severity Rating Scale [C-SSRS]), Questionnaire for Impulsive-Compulsive Disorders in PD-Rating Scale (QUIP RS), excessive daytime sleepiness (Epworth Sleepiness Scale [ESS]), vital signs, laboratory tests, and electrocardiogram (ECG) data.

    Further Safety Objective assessed based on 24 month data (for the patients who continue to the optional treatment extension):
    • To assess the long-term safety (systemic and local) and tolerability of continuous SC infusion of ND0612. Assessment will be based on AEs, with a focus on infusion site skin reactions and infusion site inspections for erythema, edema, pain, hematoma and nodules (local safety).
    .
    Objetivos de seguridad adicionales(evaluación basada en los datos de 12meses):
    •Evaluar más detalladamente seguridad y tolerabilidad de ND0612,lo que incluye la suicidalidad(Escala Columbia para evaluar la seriedad de la ideación suicida[C-SSRS]),el Cuestionario de conductas impulsivas y compulsivas en la enfermedad de Parkinson-Escala para la evaluación(QUIP RS),la somnolencia diurna excesiva(Escala de somnolencia de Epworth[ESS]),las constantes vitales,las pruebas de laboratorio y los datos de electrocardiogramas
    Objetivo de seguridad adicional evaluado sobre la base de los datos de 24meses(para los pacientes que sigan la prolongación opcional del tratamiento):
    •Evaluar seguridad a largo plazo(sistémica y local)y tolerabilidad de la perfusión SC continua de ND062.La evaluación se basará en los EfectosAdversos,con un foco en las reacciones cutáneas en el lugar de perfusión e inspecciones del lugar de perfusión para detectar eritema,edema, dolor,hematomas y nódulos(seguridad local)
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    To be eligible for study entry subjects in Cohort 1 (previously completed the treatment period in protocol ND0612H-006 within one month prior to enrolling to ND0612H-012) must satisfy all of the following criteria:
    1.Subject is able to, and has signed an Institutional Review Board/Ethics Committee (IRB/EC)-approved informed consent form (ICF).
    2.Subject has completed the treatment period of study ND0612H-006 not more than one month prior to enrolling in ND0612H-012.
    3.Willing and able to administer the SC infusion alone or with the assistance of a study partner and able to comply with the study specific procedures.

    To be eligible for study entry subjects in Cohort 2 (ND0612 naïve subjects and subjects who completed treatment in a ND0612 clinical study more than one month before screening) must satisfy all of the following criteria:
    1.Male and female PD subjects of any race aged at least 30 years who sign an IRB/EC-approved ICF.
    2.PD diagnosis consistent with the UK Brain Bank Criteria.
    3.Modified Hoehn & Yahr scale in “ON” state of stage ≤3.
    4.Taking at least 4 doses/day of LD/DDI (or at least 3 doses/day of Rytary) and taking, or have attempted to take, at least one other PD treatment for at least 30 days.
    5.Subjects must be stable on their anti-PD medications for at least 30 days before Day 1.
    6.Subjects may have had prior exposure to SC apomorphine injections/infusion but must have stopped continuous apomorphine administration at least 4 weeks before the screening visit. Treatment with apomorphine is prohibited during the entire ND0612 treatment period.
    7.Must have a minimum of 2 hrs of “OFF” time per day with predictable early morning “OFF” periods as estimated by the subject.
    8.Must have predictable and well defined early morning “OFF” periods with a good response to LD for treatment of the early morning “OFF” in the judgement of the investigator.
    9.Mini Mental State Examination (MMSE) score >26.
    10.No clinically significant medical, psychiatric or laboratory abnormalities which the investigator judges would be unsafe or non-compliant in the study.
    11.Female subjects must be surgically sterile (hysterectomy, bilateral oophorectomy, or tubal ligation), postmenopausal (defined as cessation of menses for at least 1 year), or willing to practice a highly effective method of contraception. All female participants must be non-lactating and non-pregnant and have a negative urine pregnancy test at Screening and at Baseline. Female subjects of childbearing potential must practice a highly effective method of contraception (e.g., oral contraceptives, intrauterine devices, partner with vasectomy), 1 month before enrollment, for the duration of the study, and 3 months after the last dose of study drug. Alternatively, true abstinence is acceptable when it is in line with the subject’s preferred and usual lifestyle. If a subject is usually not sexually active but becomes active, the subject and sexual partner must comply with the contraceptive requirements detailed above.
    12.Willing and able to administer the SC infusion alone or with the assistance of a study partner after a screening period of up to 40 days and willing and able to comply with study requirements.
    13. Subjects should have a named study partner
    Para ser elegibles para participar en el estudio, los sujetos de la Cohorte 1 (han finalizado con anterioridad el período de tratamiento del protocolo ND0612H-006 dentro del plazo de un mes antes de su inclusión en el estudio ND0612H-012) deben satisfacer los siguientes criterios:
    1. El sujeto es capaz de otorgar su consentimiento y ha firmado un documento de consentimiento informado (DCI) aprobado por un Comité Ético de la Investigación (CEI).
    2. El sujeto ha finalizado el período de tratamiento del estudio ND0612H-006 menos de un mes antes de su inclusión en el estudio ND0612H-012.
    3. El sujeto desea y puede administrarse la perfusión SC por sí solo o con la ayuda de un compañero del estudio, y es capaz de realizar los procedimientos específicos del estudio.
    Para ser elegibles para participar en el estudio, los sujetos de la Cohorte 2 (sujetos que nunca antes han recibido ND0612 y sujetos que han finalizado el período de tratamiento de un estudio de ND0612 más de un mes antes de la selección) deben satisfacer los siguientes criterios:
    1. Sujetos con EP de ambos sexos y de cualquier raza de cómo mínimo 30 años que hayan firmado un DCI aprobado por un CEI.
    2. Diagnóstico de EP conforme a los Criterios del Banco de Cerebros del Reino Unido.
    3. Escala de Hoehn y Yahr modificada en estado «ON» de ≤ 3.
    4. Tomar al menos 4 dosis/día de LD/IDD (o al menos 3 dosis/día de Rytary) y tomar, o haber intentado tomar, como mínimo otro tratamiento para la EP durante al menos 30 días.
    5. Los sujetos deben tener una dosis estable de sus medicamentos anti-EP durante al menos 30 días antes del Día 1.
    6. Los sujetos pueden haber estado expuestos con anterioridad a inyecciones/perfusiones SC de apomorfina, pero su administración continua de apomorfina debe haber finalizado como mínimo 4 semanas antes de la visita de selección. El tratamiento con apomorfina está prohibido durante todo el período de tratamiento con ND0612.
    7. Deben tener un mínimo de 2 horas de tiempo «OFF» al día con períodos «OFF» predecibles por la mañana temprano, según indiquen los sujetos.
    8. En opinión del investigador, deben tener períodos «OFF» predecibles y bien definidos por la mañana temprano con una buena respuesta a LD para el tratamiento del tiempo «OFF» por la mañana temprano.
    9. Puntuación en el Mini-examen cognoscitivo (MEC) de ≥ 26.
    10. Ninguna anomalía médica, psiquiátrica o analítica clínicamente significativa que, a juicio del investigador, sea insegura o no cumpla los criterios del estudio.
    11. Los sujetos de sexo femenino deben haberse sometido a una esterilización quirúrgica (histerectomía, ovariectomía bilateral o ligadura de trompas), estar en la posmenopausia (definida como cese de la menstruación durante al menos 1 año) o estar dispuestas a utilizar un método anticonceptivo altamente eficaz. Ninguna participante de sexo femenino debe estar amamantando ni embarazada, y todas deben hacerse una prueba de orina con resultado negativo en el período de selección y en el período inicial. Las participantes de sexo femenino en edad fértil deben utilizar un método anticonceptivo altamente eficaz (por ejemplo, anticonceptivos orales, dispositivos intrauterinos, pareja sometida a vasectomía) 1 mes antes de su inclusión, mientras dure el estudio y durante 3 meses después de la última dosis de fármaco del estudio. De manera alternativa, se acepta la abstinencia mientras esté en consonancia con el estilo de vida preferido y habitual del sujeto. Si normalmente un sujeto no es sexualmente activo pero se vuelve activo, el sujeto y su pareja sexual deben cumplir con los requisitos anticonceptivos detallados anteriormente.
    12. Los sujetos desean y pueden administrarse la perfusión SC por sí solos o con la ayuda de un compañero del estudio después de un período de selección de hasta 40 días y desean y pueden cumplir con los requisitos del estudio.
    13. Los sujetos deben tener un compañero de estudio designado.
    E.4Principal exclusion criteria
    Subjects in Cohort 1 and Cohort 2 will be excluded from the study if one or more of the following criteria listed below are applicable.
    1.Previously unable to tolerate ND0612 and/or have experienced intolerable adverse drug reactions associated with its use, regardless of the dosing regimen administered.

    For Cohort 2 the following exclusion criteria apply:
    1.Atypical or secondary parkinsonism.
    2.Acute psychosis or hallucinations in past 6 months.
    3.Any relevant medical, surgical, or psychiatric condition, laboratory value, or concomitant medication which, in the opinion of the Investigator makes the subject unsuitable for study entry or potentially unable to complete all aspects of the study.
    4.Any malignancy in the 5 years prior to randomization (excluding basal cell carcinoma of the skin or cervical carcinoma in situ that have been successfully treated).
    5.Positive serum serology for Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) or Human Immunodeficiency Virus (HIV) at the Screening visit
    6.Prior neurosurgical procedure for PD, or Duodopa treatment
    7.Subjects with a history of drug abuse or alcoholism within the past 12 months.
    8.Clinically significant ECG rhythm abnormalities.
    9.Renal or liver dysfunction that may alter drug metabolism including: serum creatinine >1.3 mg/dL, serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2 x upper limit of normal (ULN), total serum bilirubin >2.5 mg/dL.
    10. Current participation in a clinical trial with an investigational product or past participation within the last 30 days.
    Para la Cohorte 1 y la Cohorte 2 se aplican los siguientes criterios de exclusión:
    1. Incapaces de tolerar anteriormente ND0612 y/o haber sufrido reacciones adversas intolerables al fármaco asociadas con su uso, con independencia de la pauta posológica administrada.
    Para la Cohorte 2 se aplican los siguientes criterios de exclusión:
    1. Parkinsonismo atípico o secundario.
    2. Psicosis o alucinaciones agudas los últimos 6 meses.
    3. Cualquier trastorno médico, quirúrgico o psiquiátrico pertinente, valor analítico o medicamento concomitante que, en opinión del investigador, haga que no sea adecuado incluir al sujeto en el estudio o que este no pueda completar todos los aspectos del estudio.
    4. Cualquier neoplasia maligna en los 5 años anteriores a la aleatorización (excluidos el carcinoma basocelular de la piel o el carcinoma cervical localizado tratado con éxito).
    5. Prueba sérica positiva para el virus de la hepatitis B (VHB), el virus de la hepatitis C (VHC) o el virus de la inmunodeficiencia humana (VIH) en la visita de selección.
    6. Procedimiento neuroquirúrgico anterior para tratar la EP o tratamiento con Duodopa.
    7. Sujetos con historia de alcoholismo o drogadicción en los últimos 12 meses.
    8. Anomalías en el ritmo de los ECG clínicamente significativas.
    9. Disfunción renal o hepática susceptible de alterar el metabolismo del fármaco: creatinina sérica >1,3 mg/dl, aspartato aminotransferasa (AST) sérica o alanina aminotransferasa (ALT) sérica >2 veces el límite superior de la normalidad (LSN), bilirrubina sérica total >2,5 mg/dl.
    10. Estar participando actualmente en un ensayo clínico con un producto en fase de investigación o haber participado en uno en los últimos 30 días.
    E.5 End points
    E.5.1Primary end point(s)
    The primary endpoint in this study is a safety endpoint assessing AEs, with a focus on infusion site skin reactions of continuous SC infusion of ND0612 throughout the study period. Local safety at the infusion sites will be assessed as the proportion of subjects with clinically significant skin reactions and severity of skin reactions according to the following local safety parameters: erythema, edema, pain, hematoma and nodules.
    El criterio principal de valoración en este estudio es un criterio de valoración de la seguridad que evalúa los AA, haciendo especial hincapié en las reacciones cutáneas en el lugar de la perfusión SC continua de ND0612 durante todo el período del estudio. La seguridad local en los lugares de la perfusión se evaluará como la proporción de sujetos con reacciones cutáneas clínicamente significativas, y la gravedad de las reacciones cutáneas se evaluará según los siguientes parámetros de seguridad local: eritema, edema, dolor, hematomas y nódulos.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Month 12 visit
    Visita del Mes 12
    E.5.2Secondary end point(s)
    Tolerability will be assessed based on percentage of subjects completing the trial.

    The exploratory efficacy endpoints are:
    * Change in daily “OFF” time from Baseline to the 12 month visit, based on home diaries
    * Change in daily “ON” time without troublesome dyskinesia (defined as the sum of "ON" time without dyskinesia and “ON” time with non-troublesome dyskinesia) based on home "ON OFF" diaries
    * Change in total daily dose of oral LD/DDI from Baseline to the 12 month visit
    * Change in PDQ-39 scores from Baseline to the 12 month visit
    * Change in EQ-5D-5L scores from Baseline to the 12 month visit
    * Change in UPDRS Part II (ADL) from Baseline to the 12 month visit
    * Change in CGI-Severity and CGI-Improvement from Baseline to the 12 month visit
    * Change in SGI-Improvement from Baseline to the 12 month visit
    * Change in PDSS total score from Baseline to the 12 month visit
    * Change in UPDRS Part III (motor score) from Baseline to the 12 month visit
    La tolerabilidad se evaluará como el porcentaje de sujetos que completen el ensayo.

    Los criterios exploratorios de valoración de la eficacia son:
    • Cambio en el tiempo «OFF» diario desde la visita inicial hasta la visita del Mes 12, según los diarios rellenados en casa.
    • Cambio en el tiempo «ON» diario sin discinesia problemática (definido como la suma del tiempo «ON» sin discinesia y el tiempo «ON» con discinesia no problemática) según el diario «ON/OFF» rellenado en casa
    • Cambio en la dosis total diaria de LD/IDD oral desde la visita inicial hasta la visita del Mes 12
    • Cambio en las puntuaciones del PDQ-39 desde la visita inicial hasta la visita del Mes 12
    • Cambio en las puntuaciones del EQ-5D-5L desde la visita inicial hasta la visita del Mes 12
    • Cambio en la UPDRS parte II (AVC) desde la visita inicial hasta la visita del Mes 12
    • Cambio en la GCI-Gravedad y la CGI-Mejora desde la visita inicial hasta la visita del Mes 12
    • Cambio en la SGI-Mejora desde la visita inicial hasta la visita del Mes 12
    • Cambio en la puntuación total de la PDSS desde la visita inicial hasta la visita del Mes 12
    • Cambio en la UPDRS parte III (puntuación motora) desde la visita inicial hasta la visita del Mes 12
    E.5.2.1Timepoint(s) of evaluation of this end point
    Month 12 visit
    Visita del Mes 12
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    Se estudiarán 2 dosis de IMP: Pauta 1 (720 LD / 90 CD mg) vs Pauta 3 (720LD / 90 CD mg)
    2 dosages of IMP will be studied: Regimen 1 (720 LD/90 CD mg) vs Regimen 3 (720LD / 90 CD mg)
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned6
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA60
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Austria
    Belgium
    Czech Republic
    France
    Germany
    Hungary
    Israel
    Italy
    Poland
    Russian Federation
    Spain
    Ukraine
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    Última visita del ultimo paciente
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months3
    E.8.9.1In the Member State concerned days40
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months4
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 74
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 96
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others Information not present in EudraCT
    F.4 Planned number of subjects to be included
    F.4.1In the member state6
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 88
    F.4.2.2In the whole clinical trial 170
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    If the product is not commercially available at the end of the study (after 12 month treatment period), subjects will be allowed to consent for optional 12 month treatment with their assigned treatment regimen until NeuroDerm either ceases development of the ND0612 product or it becomes commercially available; otherwise subjects will revert to normal standard of care .
    Si el producto no está disponible comercialmente al final del studio (después de 12 meses de periodo de tratamiento), se les permitirá a los sujetos consentir para un tratamiento opcional de 12 meses con la pauta de tratamiento asignado hasta que NeuroDerm deje de desarrollar el producto ND0612 o esté comercialmente disponible; de lo contrario los sujetos volverán a su atención médica estándar o normal.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2017-06-22
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2017-05-25
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2021 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA